Parkinson’s Disease Treatment Market, [By Drug Type (Dopamine Receptor Agonist, Carbidopa/Levodopa, MAO-Inhibitors, Others); By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy); By End Use (Hospital, Clinics)]; and Geography - Trend, Analysis and Forecast till 2025

报告摘要

全球帕金森病治疗市场注意到普遍存在的普遍存在，并提高对初始阶段帕金森病诊断的认识。

帕金森病（PD）是一种神经变性障碍，这是由于大脑中多巴胺产生的丧失引起的。它导致影响大脑的人体在人体中的运动功能的逐渐恶化和神经细胞。它可以一方面识别几乎没有明显的震颤，但是最重要的症状之一，可以帮助医生在早期阶段识别帕金森病。由于各种环境因素和遗传突变，帕金森病明显引起。此外，它还导致思维困难，抑郁和情绪变化，吞咽问题，睡眠障碍，便秘和膀胱问题等问题。

帕金森的疾病是阿尔茨海默氏症后的第二个最常见的神经退行性疾病。全球患有帕金森病的人数约为1000万，或者在每1,00,000人中约有41人。男人可能会受到比一个女人高的1.5倍。

帕金森病，可以通过减少武器的运动，在行走，僵硬，执行任务方面减少。此外，一些次要症状包括焦虑，抑郁和痴呆。这种疾病在60岁左右的人中发现，并且疾病的减值因人的人而异。该研究表明，在大脑中观察到初级症状约60％至80％的多巴胺产生细胞的时间受损。由于神经元分裂，导致脑活动丧失以及帕金森病的某些迹象引起了对脑细胞的这种损害。

始终如一地增加了老年人的人口，增加了研究和发展的资金，以及有利的政府政策将支持全球帕金森病治疗市场的增长。

市场主要是由prevalenc上升e of Parkinson’s disease, due to increased life expectancy across the globe. For instance, the data presented by WHO in 2015, stated the average ‘life expectancy of a person was 70 years and would continue to increase. Additionally, a continuous surge in the investment by the leading players for discovering various treatment options for PD. Geographically, Japan has the highest life expectancy which makes it an effective location. Thus, the leading companies focus has now shifted toward the developing countries.

While, increasing number of clinical trials for understanding the pathophysiology of Parkinson’s diseases, and growing R&D funding and investments on healthcare by the governments of developing economies, and unmet needs for effective treatments influence the market growth during the forecast period.

此外，包括增加药水管道的关键趋势，基因治疗范围的数量升高，患有帕金森疾病的人数升高的人的增长。

全球帕金森病治疗市场分类

全球市场基于药物类型，分销渠道，最终使用和地理分段

在药物类型的基础上，市场分段为：

• Dopamine Receptor Agonist
• Carbidopa/Levodopa
• 毛抑制剂
• Others

On the basis of distribution channel, the market is segmented into:

• 医院药店
• Online Pharmacies
• 零售药房

On the basis of end use type, the market is segmented into:

• Hospital
• Clinics

Geographically, the global Parkinson’s disease treatment market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Rising awareness about Parkinson disease, increasing geriatric population and continuous government efforts to support gene therapy to lead the growth of this market in Europe.

Europe region is expected to dominate the global Parkinson’s disease treatment market over the forecast period. Europe holds major share owning to the continuous technological developments by the increasing R&D investments.

虽然，北美被认为是在地区的第二大市场份额，但亚太地区预计预测期间会迅速增长。在发展医疗保健基础设施的支出方面，生长患者依据以及各国政府的支出是预计在即将到来的几年期间预测亚洲太平洋地区帕金森病治疗的增长的主要因素。yabo娱乐vip

全球帕金森病治疗市场的主要球员是：

• Teva Pharmaceuticals Inc.
• Novartis AG
• glaxosmithkline Inc.
• ABBVIE Inc.
• 默克和公司
• Boehringer Ingelheium Inc.
• Impax Laboratories
• 太阳制药
• 缬草药业
• UCB Inc.。